375 related articles for article (PubMed ID: 16125590)
41. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.
Mehta J; Singhal S; Gee AP; Chiang KY; Godder K; Rhee Fv Fv; DeRienzo S; O'Neal W; Lamb L; Henslee-Downey PJ
Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338
[TBL] [Abstract][Full Text] [Related]
42. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
[TBL] [Abstract][Full Text] [Related]
43. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
44. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
45. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.
Alyea EP; Weller E; Fisher DC; Freedman AS; Gribben JG; Lee S; Schlossman RL; Stone RM; Friedberg J; DeAngelo D; Liney D; Windawi S; Ng A; Mauch P; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2002; 8(11):601-7. PubMed ID: 12463479
[TBL] [Abstract][Full Text] [Related]
46. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
47. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Hale G; Waldmann H
Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
[TBL] [Abstract][Full Text] [Related]
48. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
49. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
[TBL] [Abstract][Full Text] [Related]
50. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.
Yagasaki H; Kojima S; Yabe H; Kato K; Kigasawa H; Sakamaki H; Tsuchida M; Kato S; Kawase T; Muramatsu H; Morishima Y; Kodera Y
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085
[TBL] [Abstract][Full Text] [Related]
51. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
[TBL] [Abstract][Full Text] [Related]
52. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate.
Kanda Y; Izutsu K; Hirai H; Sakamaki H; Iseki T; Kodera Y; Okamoto S; Mitsui H; Iwato K; Hirabayashi N; Furukawa T; Maruta A; Kasai M; Atsuta Y; Hamajima N; Hiraoka A; Kawa K
Leukemia; 2004 May; 18(5):1013-9. PubMed ID: 15029208
[TBL] [Abstract][Full Text] [Related]
53. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
[TBL] [Abstract][Full Text] [Related]
54. Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease.
Aschan J; Ringdén O; Sundberg B; Klaesson S; Ljungman P; Lönnqvist B
Eur J Haematol; 1993 May; 50(5):269-74. PubMed ID: 8319789
[TBL] [Abstract][Full Text] [Related]
55. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.
Sullivan KM; Storb R; Buckner CD; Fefer A; Fisher L; Weiden PL; Witherspoon RP; Appelbaum FR; Banaji M; Hansen J
N Engl J Med; 1989 Mar; 320(13):828-34. PubMed ID: 2648143
[TBL] [Abstract][Full Text] [Related]
56. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
[TBL] [Abstract][Full Text] [Related]
57. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases.
McGlave PB; Beatty P; Ash R; Hows JM
Blood; 1990 Apr; 75(8):1728-32. PubMed ID: 2328322
[TBL] [Abstract][Full Text] [Related]
58. T-cell depletion to prevent GVHD after unrelated-donor marrow transplantation.
Locatelli F; De Stefano P
Lancet; 2005 Aug 27-Sep 2; 366(9487):692-4. PubMed ID: 16125569
[No Abstract] [Full Text] [Related]
59. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
[TBL] [Abstract][Full Text] [Related]
60. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
